ES2173846T3 - Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. - Google Patents

Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.

Info

Publication number
ES2173846T3
ES2173846T3 ES00305372T ES00305372T ES2173846T3 ES 2173846 T3 ES2173846 T3 ES 2173846T3 ES 00305372 T ES00305372 T ES 00305372T ES 00305372 T ES00305372 T ES 00305372T ES 2173846 T3 ES2173846 T3 ES 2173846T3
Authority
ES
Spain
Prior art keywords
alkyl
halogen
alkoxy
biciclocarbonil
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00305372T
Other languages
English (en)
Inventor
Shigeo Hayashi
Rodney William Stevens
Kazunari Nakao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2173846T3 publication Critical patent/ES2173846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula **fórmula** o las sales farmacéuticamente aceptables del mismo, en la que A es alquileno C1-6 o NR1 -; Z es C(=L)R2, o SO2R3; U es CH o N; W e Y se seleccionan independientemente entreCH2-, O, S y N-R1; m es 1, 2 ó 3; q y r son, independientemente, 0, 1 ó 2; X se selecciona independientemente a partir de halógeno, alquilo C1-4, alquilo C1-4 sustituido con halógeno, hidroxi, alcoxi C1-4, alcoxi C1-4 sustituido con halógeno, alquil C1-4-tio, nitro, amino, mono o di-(alquil C1-4)amino y ciano; n es 0, 1, 2, 3 ó 4; L es oxígeno o azufre; R1 es hidrógeno o alquilo C1-4; R2 es hidroxi, alquilo C1-6, alquilo C1-6 sustituido con halógeno, alcoxi C1-6, alcoxi C1-6 sustituido con halógeno, cicloalcoxilo C3-7, alquil-C1-4 (cicloalcoxil C3- 7), -N-R4R5, alquil C1-4 -fenil-O- o fenil-O-, estando dicho fenilo sustituido opcionalmente con 1 a 5 sustituyentes seleccionados independientemente a partir de halógeno, alquilo C1-4, hidroxi, alcoxi C1-4 y nitro; R3 es un alquilo C1-6 oun alquilo C1-6 sustituido con halógeno; y R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo C1-6 y alquilo C1-6 sustituido con halógeno.
ES00305372T 1999-07-02 2000-06-26 Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. Expired - Lifetime ES2173846T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB99/01243 1999-07-02

Publications (1)

Publication Number Publication Date
ES2173846T3 true ES2173846T3 (es) 2002-11-01

Family

ID=11004872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00305372T Expired - Lifetime ES2173846T3 (es) 1999-07-02 2000-06-26 Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.

Country Status (11)

Country Link
US (1) US6303628B1 (es)
EP (1) EP1065204B1 (es)
JP (1) JP3333179B2 (es)
AT (1) ATE215945T1 (es)
BR (1) BR0002936A (es)
CA (1) CA2313122C (es)
DE (1) DE60000120T2 (es)
DK (1) DK1065204T3 (es)
ES (1) ES2173846T3 (es)
MX (1) MXPA00006605A (es)
PT (1) PT1065204E (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
HUP0401499A3 (en) * 2001-09-27 2007-05-02 Hoffmann La Roche Indole derivatives as cox ii inhibitors, process for their preparation and pharmaceutical compositions containing them
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
MXPA04010186A (es) * 2002-04-18 2005-02-03 Pharmacia Corp Monoterapia para el tratamiento de la enfermedad de parkinson con inhibidor (es) de la ciclooxigenasa-2 (cox 2).
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
AU2003299757A1 (en) * 2002-12-19 2004-07-14 Elan Pharmaceuticals Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
US9695118B2 (en) 2012-04-24 2017-07-04 Chugai Seiyaku Kabushiki Kaisha Benzamide derivative
KR20150003849A (ko) 2012-04-24 2015-01-09 추가이 세이야쿠 가부시키가이샤 퀴나졸린디온 유도체
KR20160073413A (ko) 2013-10-23 2016-06-24 추가이 세이야쿠 가부시키가이샤 퀴나졸리논 및 이소퀴놀리논 유도체
WO2016114816A1 (en) * 2015-01-18 2016-07-21 Sri International MAP4K4 (HGK) Inhibitors
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
BR9606619A (pt) 1995-09-01 1997-12-23 Lilly Co Eli Antagonistas do receptor de neuropeptídeo y indolil
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.

Also Published As

Publication number Publication date
CA2313122A1 (en) 2001-01-02
MXPA00006605A (es) 2004-12-09
EP1065204A4 (en) 2000-11-15
ATE215945T1 (de) 2002-04-15
EP1065204A1 (en) 2001-01-03
JP2001031677A (ja) 2001-02-06
JP3333179B2 (ja) 2002-10-07
US6303628B1 (en) 2001-10-16
DE60000120D1 (de) 2002-05-16
CA2313122C (en) 2004-08-24
DK1065204T3 (da) 2002-07-22
DE60000120T2 (de) 2002-08-14
EP1065204B1 (en) 2002-04-10
PT1065204E (pt) 2002-08-30
BR0002936A (pt) 2001-04-03

Similar Documents

Publication Publication Date Title
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
PE20020532A1 (es) Derivados de naftaleno como agonistas del receptor canabinoide
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
CR7387A (es) Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas
DE69530511D1 (de) Enantioselective herstellung von pharmazeutisch aktiven sulfoxiden durch bioreduktion
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
ES2178451T3 (es) Derivados de benzoxadiazoles, benzotiadiazoles, benzotriazoles y quinoxalinas.
CO5031250A1 (es) Compuesto farmaceutico
DE60332350D1 (de) Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten
BG104287A (en) Halogensubstituted tetracyclic derivatives of tetrahydrofuran
ATE248897T1 (de) Anthrachinonverbindungen und ihre derivate
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
IS1726B (is) Hliðstæðar aðferðir til framleiðslu á andróstenónafleiðu og milliefni notuð í aðferðunum
AR059282A1 (es) Derivados del acido 1,3-dihidro-2h-benzo[f]isoindol acetico, metodo de preparacion, composiciones farmaceuticas que los contienen y usos terapeuticos como agonistas de receptores ep4.
HUP9801072A2 (hu) Szubsztituált 6-és 7-amino-tetrahidro-izokinolin-karbonsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1065204

Country of ref document: ES